Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and Asia.

Date publication

août 2022

Journal

Radiation oncology (London, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr QUIVRIN Magali

Tous les auteurs :
Slotman BJ, Clark MA, Özyar E, Kim M, Itami J, Tallet A, Debus J, Pfeffer R, Gentile P, Hama Y, Andratschke N, Riou O, Camilleri P, Belka C, Quivrin M, Kim B, Pedersen A, van Overeem Felter M, Kim YI, Kim JH, Fuss M, Valentini V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35996192

Résumé

Magnetic resonance-guided radiotherapy (MRgRT) utilization is rapidly expanding, driven by advanced capabilities including better soft tissue imaging, continuous intrafraction target visualization, automatic triggered beam delivery, and the availability of on-table adaptive replanning. Our objective was to describe patterns of 0.35 Tesla (T)-MRgRT utilization in Europe and Asia among early adopters of this novel technology.

Mots clés

ART, Care patterns, MR-IGRT, MRI-guided radiotherapy, On-table adaptive radiation therapy, SABR, SBRT, Stereotactic ablative radiation therapy, Stereotactic body radiotherapy, oART

Référence

Radiat Oncol. 2022 08 22;17(1):146